Pipeline - Takeda Oncology
Our Pipeline
Our Pipeline
Our oncology R&D activities are focused on translating science into curative or transformative potential treatments through novel strategies that leverage the untapped power of innate immunity.
These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.
| Investigational therapy | Platform | Investigational indication | Phase | ||
Cabozantinib* | |||||
Targeted therapy | Metastatic castration-resistant prostate cancer (JP) | Phase 3 | |||
Fruquintinib* | |||||
Targeted therapy | Refractory metastatic colorectal cancer | Phase 3 | |||
Ixazomib* | |||||
Proteasome inhibitor | Maint. newly diagnosed multiple myeloma post- stem cell transplant (US, EU) | Phase 3 | |||
Mobocertinib* | |||||
Targeted therapy | 2L EGFR Exon20 insertion non-small cell lung cancer (JP) | Phase 3 | |||
Targeted therapy | 1L EGFR Exon20 insertion non-small cell lung cancer | Phase 3 | |||
Ponatinib* | |||||
Targeted therapy | FL Ph+ acute lymphocytic leukemia (US) | Phase 3 | |||
Targeted therapy | Pediatric Ph+ acute lymphoblastic leukemia | Phase 1 | |||
Relugolix* (TAK-385) | |||||
Small molecule | Prostate cancer (JP, Asian countries) | Phase 3 | |||
Modakafusp Alfa (TAK-573) | |||||
Innate immunity enhancer | Multiple myeloma | Phase 1/2 | |||
Innate immunity enhancer | Solid tumors | Phase 1/2 | |||
Subasumstat (TAK-981) | |||||
Innate immunity enhancer | Multiple cancers | Phase 1/2 | |||
TAK-007 | |||||
Redirected immunity | B-cell malignancies | Phase 2 | |||
TAK-186 | |||||
Redirected immunity | Solid tumors | Phase 1/2 | |||
TAK-102 | |||||
Redirected immunity | Solid tumors | Phase 1 | |||
TAK-103 | |||||
Redirected immunity | Solid tumors | Phase 1 | |||
TAK-500 | |||||
Innate immunity enhancer | Solid tumors | Phase 1 | |||
TAK-676 | |||||
Innate immunity enhancer | Solid tumors | Phase 1 | |||
TAK-940 | |||||
Redirected immunity | B-cell malignancies | Phase 1 | |||
TAK-280 | |||||
Redirected immunity | Solid tumors | Phase 1/2 |
*Marketed products have received approval in one or more jurisdictions.
All programs have global development rights unless otherwise noted.
GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets
Investors
To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page
